Targeted delivery of galbanic acid to colon cancer cells by PLGA nanoparticles incorporated into human mesenchymal stem cells

Document Type : Original Research Article


1 Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of Immunology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran

3 Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

4 Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

5 Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

6 Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran


Objective: The aim of this study was to investigate the efficacy of mesenchyme stem cells (MSCs) derived from human adipose tissue (hMSCs) as carriers for delivery of galbanic acid (GBA), a potential anticancer agent, loaded into poly (lactic-co-glycolic acid) (PLGA) nanoparticles (nano-engineered hMSCs) against tumor cells.  
Materials and Methods: GBA-loaded PLGA nanoparticles (PLGA/GBA) were prepared by single emulsion method and their physicochemical properties were evaluated. Then, PLGA/GBA nanoparticles were incorporated into hMSCs (hMSC/PLGA-GBA) and their migration ability and cytotoxicity against colon cancer cells were investigated.  
Results: The loading efficiency of PLGA/GBA nanoparticles with average size of 214±30.5 nm into hMSCs, was about 85 and 92% at GBA concentration of 20 and 40 μM, respectively. Nano-engineered hMSCs showed significant higher migration to cancer cells (C26) compared to normal cells (NIH/3T3). Furthermore, nano-engineered hMSCs could effectively induce cell death in C26 cells in comparison with non-engineered hMSCs. 
Conclusion: hMSCs could be implemented for efficient loading of PLGA/GBA nanoparticles to produce a targeted cellular carrier against cancer cells. Thus, according to minimal toxicity on normal cells, it deserves to be considered as a valuable platform for drug delivery in cancer therapy.


Afsharzadeh M, Abnous K, Yazdian–Robati
R, Ataranzadeh A, Ramezani M, Hashemi
M. 2019. Formulation and evaluation of
anticancer and antiangiogenesis efficiency
of PLA–PEG nanoparticles loaded with
galbanic acid in C26 colon carcinoma, in
vitro and in vivo. J Cell Physiol, 234:
Ebrahimian et al.
AJP, Vol. 12, No. 3, May-Jun 2022 306
Afsharzadeh M, Hashemi M, Babaei M,
Abnous K, Ramezani M. 2020. PEG‐PLA
nanoparticles decorated with small‐
molecule PSMA ligand for targeted
delivery of galbanic acid and docetaxel to
prostate cancer cells. J Cell Physiol, 235:
Azimifar MA, Salmasi Z, Doosti A, Babaei N,
Hashemi M. 2021. Evaluation of the
efficiency of modified PAMAM dendrimer
with low molecular weight protamine
peptide to deliver IL‐12 plasmid into stem
cells as cancer therapy vehicles. Biotechnol
Prog, 37: e3175.
Charbgoo F, Taghdisi SM, Yazdian‐Robati R,
Abnous K, Ramezani M, Alibolandi M.
2020. Aptamer‐incorporated nanoparticle
systems for drug delivery. In:
Nanobiotechnology in Diagnosis, Drug
Delivery, and Treatment, pp. 95-112,
Chulpanova DS, Kitaeva KV, Tazetdinova
LG, James V, Rizvanov AA, Solovyeva
VV. 2018. Application of mesenchymal
stem cells for therapeutic agent delivery in
anti-tumor treatment. Front Pharmacol, 9:
Ding D, Zhu Q. 2018. Recent advances of
PLGA micro/nanoparticles for the delivery
of biomacromolecular therapeutics. Mater
Sci Eng C, 92: 1041-1060.
Du X, Xue J, Jiang M, Lin S, Huang Y, Deng
K, Shu L, Xu H, Li Z, Yao J. 2021. A
multiepitope peptide, rOmp22,
encapsulated in chitosan-PLGA
nanoparticles as a candidate vaccine against
Acinetobacter baumannii infection. Int J
Nanomedicine, 16: 1819-1836.
Ebrahimian M, Hashemi M, Maleki M,
Abnous K, Hashemitabar G, Ramezani M,
Haghparast A. 2016. Induction of a
balanced Th1/Th2 immune responses by
co-delivery of PLGA/ovalbumin
nanospheres and CpG ODNs/PEI-SWCNT
nanoparticles as TLR9 agonist in BALB/c
mice. Int J Pharm, 515: 708-720.
Ebrahimian M, Hashemi M, Maleki M,
Hashemitabar G, Abnous K, Ramezani M,
Haghparast A. 2017. Co-delivery of dual
toll-like receptor agonists and antigen in
poly (lactic-co-glycolic)
acid/polyethylenimine cationic hybrid
nanoparticles promote efficient in vivo
immune responses. Front Immunol, 8:
Eskandani M, Abdolalizadeh J, Hamishehkar
H, Nazemiyeh H, Barar J. 2015. Galbanic
acid inhibits HIF-1α expression via
EGFR/HIF-1α pathway in cancer cells.
Fitoterapia, 101: 1-11.
Gao Z, Zhang L, Hu J, Sun Y. 2013.
Mesenchymal stem cells: a potential
targeted-delivery vehicle for anti-cancer
drug loaded nanoparticles. Nanomed:
Nanotechnol Biol Med, 9: 174-184.
Gharedaghi Kloucheh S, Khoubanfar H,
Moghaddam Matin M, Behnam Rassouli F,
Investigating effects of galbanic acid on the
viability of LoVo colon carcinoma cells,
2021, Proceedings of the 21st International
and 9th National Congress in Biology,
Semnan, Iran.
Hafezi Ghahestani Z, Alebooye Langroodi F,
Mokhtarzadeh A, Ramezani M, Hashemi
M. 2017. Evaluation of anti-cancer activity
of PLGA nanoparticles containing crocetin.
Artif Cells Nanomed Biotechnol, 45: 955-
Hashemi M, Abnous K, Balarastaghi S,
Hedayati N, Salmasi Z, Yazdian-Robati R.
2022. Mitoxantrone-loaded PLGA
nanoparticles for increased sensitivity of
glioblastoma cancer cell to TRAIL-induced
apoptosis. J Pharm Innov, 17: 207-214.
Hashemi M, Haghgoo Z, Yazdian-Robati R,
Shahgordi S, Salmasi Z, Abnous K. 2021.
Improved anticancer efficiency of
mitoxantrone by curcumin loaded PLGA
nanoparticles targeted with AS1411
aptamer. Nanomed J, 8: 21-29.
Hashemi M, Shamshiri A, Saeedi M, Tayebi
L, Yazdian-Robati R. 2020. Aptamerconjugated PLGA nanoparticles for
delivery and imaging of cancer therapeutic
drugs. Arch Biochem Biophy, 691: 108485.
Heidari R, Gholamian Dehkordi N, Mohseni
R, Safaei M. 2020. Engineering
mesenchymal stem cells: a novel
therapeutic approach in breast cancer. J
Drug Target, 28: 732-741.
Hour FQ, Moghadam AJ, Shakeri-Zadeh A,
Bakhtiyari M, Shabani R, Mehdizadeh M.
2020. Magnetic targeted delivery of the
SPIONs-labeled mesenchymal stem cells
derived from human Wharton's jelly in
Alzheimer's rat models. J Control Release,
321: 430-441.
Nano-engineered MSCs for eliminating cancer cells
AJP, Vol. 12, No. 3, May-Jun 2022 307
Huang M, Lu J-J, Ding J. 2021. Natural
products in cancer therapy: past, present
and future. Nat Prod Bioprospect, 11: 5-13.
Huang P, Russell AL, Lefavor R, Durand NC,
James E, Harvey L, Zhang C, Countryman
S, Stodieck L, Zubair AC. 2020.
Feasibility, potency, and safety of growing
human mesenchymal stem cells in space for
clinical application. NPJ Microgravity, 6:
Kim K-H, Lee H-J, Jeong S-J, Lee H-J, Lee EO, Kim H-S, Zhang Y, Ryu S-Y, Lee M-H,
Lü J. 2011. Galbanic acid isolated from
Ferula assafoetida exerts in vivo anti-tumor
activity in association with antiangiogenesis and anti-proliferation. Pharm
Res, 28: 597-609.
Krueger TE, Thorek DL, Denmeade SR,
Isaacs JT, Brennen WN. 2018. Concise
review: Mesenchymal stem cell‐based drug
delivery: The good, the bad, the ugly, and
the promise. Stem Cells Transl Med, 7:
Labusca L, Herea DD, Mashayekhi K. 2018.
Stem cells as delivery vehicles for
regenerative medicine-challenges and
perspectives. World J Stem Cells, 10: 43-
Li L, Guan Y, Liu H, Hao N, Liu T, Meng X,
Fu C, Li Y, Qu Q, Zhang Y. 2011. Silica
mesenchymal stem cells for tumor-tropic
therapy. ACS nano, 5: 7462-7470.
Lin W, Li C, Xu N, Watanabe M, Xue R, Xu
A, Araki M, Sun R, Liu C, Nasu Y. 2021.
Dual-functional PLGA nanoparticles coloaded with indocyanine green and
resiquimod for prostate cancer treatment.
Int J Nanomedicine, 16: 2775.
L Ramos T, Sánchez-Abarca LI, Muntión S,
Preciado S, Puig N, López-Ruano G,
Hernández-Hernández Á, Redondo A,
Ortega R, Rodríguez C, Sánchez-Guijo F,
del Cañizo C. 2016. MSC surface markers
(CD44, CD73, and CD90) can identify
human MSC-derived extracellular vesicles
by conventional flow cytometry. Cell
Commun Signal, 14: 2.
Mosafer J, Abnous K, Tafaghodi M,
Mokhtarzadeh A, Ramezani M. 2017. In
vitro and in vivo evaluation of antinucleolin-targeted magnetic PLGA
nanoparticles loaded with doxorubicin as a
theranostic agent for enhanced targeted
cancer imaging and therapy. Eur J Pharm
Biopharm, 113: 60-74.
Nik ME, Malaekeh-Nikouei B, Amin M,
Hatamipour M, Teymouri M, Sadeghnia
HR, Iranshahi M, Jaafari MR. 2019.
Liposomal formulation of Galbanic acid
improved therapeutic efficacy of pegylated
liposomal doxorubicin in mouse colon
carcinoma. Sci Rep, 9: 1-15.
Oh BS, Shin EA, Jung JH, Jung DB, Kim B,
Shim BS, Yazdi MC, Iranshahi M, Kim
SH. 2015. Apoptotic effect of galbanic acid
via activation of caspases and inhibition of
Mcl‐1 in H460 non‐small lung carcinoma
cells. Phytother Res, 29: 844-849.
Paris JL, de la Torre P, Manzano M, Cabañas
MV, Flores AI, Vallet-Regí M. 2016.
Decidua-derived mesenchymal stem cells
as carriers of mesoporous silica
nanoparticles. in vitro and in vivo
evaluation on mammary tumors. Acta
Biomater, 33: 275-282.
Paris JL, de la Torre P, Victoria Cabañas M,
Manzano M, Grau M, Flores AI, ValletRegí M. 2017. Vectorization of ultrasoundresponsive nanoparticles in placental
mesenchymal stem cells for cancer therapy.
Nanoscale, 9: 5528-5537.
Sajjadi M, Karimi E, Oskoueian E, Iranshahi
M, Neamati A. 2019. Galbanic acid:
induced antiproliferation in estrogen
receptor‐negative breast cancer cells and
enhanced cellular redox state in the human
dermal fibroblasts. J Biochem Mol Toxicol,
33: e22402.
Salmasi Z, Hashemi M, Mahdipour E, Nourani
H, Abnous K, Ramezani M. 2020.
Mesenchymal stem cells engineered by
modified polyethylenimine polymer for
targeted cancer gene therapy, in vitro and in
vivo. Biotechnol Prog, 36: e3025.
Salmasi Z, Mokhtarzadeh A, Hashemi M,
Ebrahimian M, Farzad SA, Parhiz H,
Ramezani M. 2018. Effective and safe in
vivo gene delivery based on polyglutamic
acid complexes with heterocyclic amine
modified-polyethylenimine. Colloids Surf
B Biointerfaces, 172: 790-796.
Semete B, Booysen L, Lemmer Y, Kalombo
L, Katata L, Verschoor J, Swai HS. 2010.
In vivo evaluation of the biodistribution
and safety of PLGA nanoparticles as drug
delivery systems. Nanomed: Nanotechnol
Biol Med, 6: 662-671.
Ebrahimian et al.
AJP, Vol. 12, No. 3, May-Jun 2022 308
Shahcheraghi SH, Lotfi M, Soukhtanloo M,
Ghayour Mobarhan M, Jaliani HZ,
Sadeghnia HR, Ghorbani A. 2021. Effects
of galbanic acid on proliferation, migration,
and apoptosis of glioblastoma cells through
the PI3K/Akt/MTOR signaling pathway.
Curr Mol Pharmacol, 14: 79-87.
Tayarani-Najaran Z, Kamali H, Hadizadeh F,
Ahmadi F, Shahidi S. 2021. Osteoblast
differentiation of human dental pulp stem
cells with dexamethasone in-situ forming
implant. J Mashhad Dent Sch, 45: 70-82.
Tripodo G, Chlapanidas T, Perteghella S,
Vigani B, Mandracchia D, Trapani A,
Galuzzi M, Tosca MC, Antonioli B,
Gaetani P. 2015. Mesenchymal stromal
cells loading curcumin-invite-micelles: A
drug delivery system for neurodegenerative
diseases. Colloids Surf B Biointerfaces,
125: 300-308.
Vallet-Regí M, Paris J, Torre P, Cabañas M,
Manzano M, Flores A. 2018. Mesenchymal
stem cells from human placenta as
nanoparticle delivery vectors. Insights Stem
Cells, 4: 1-2.
Wang X, Chen H, Zeng X, Guo W, Jin Y,
Wang S, Tian R, Han Y, Guo L, Han J, Wu
Y, Mei L. 2019. Efficient lung cancertargeted drug delivery via a
nanoparticle/MSC system. Acta Pharm Sin,
9: 167-176.
Wang X, Gao J, Ouyang X, Wang J, Sun X,
Lv Y. 2018. Mesenchymal stem cells
loaded with paclitaxel-poly (lactic-coglycolic acid) nanoparticles for gliomatargeting therapy. Int J Nanomedicine, 13:
Yao S, Li X, Liu J, Sun Y, Wang Z, Jiang Y.
2017. Maximized nanodrug-loaded
mesenchymal stem cells by a dual drugloaded mode for the systemic treatment of
metastatic lung cancer. Drug Deliv, 24:
Yin P, Gui L, Wang C, Yan J, Liu M, Ji L,
Wang Y, Ma B, Gao W-Q. 2020. Targeted
delivery of CXCL9 and OX40L by
mesenchymal stem cells elicits potent
antitumor immunity. Mol Ther, 28: 2553-
Zhang M, Kim Y-K, Cui P, Zhang J, Qiao J,
He Y, Lyu J, Luo C, Xing L, Jiang H. 2016.
Folate-conjugated polyspermine for lung
cancer–targeted gene therapy. Acta Pharm
Sin B, 6: 336-343.
Zhang X, Yao S, Liu C, Jiang Y. 2015. Tumor
tropic delivery of doxorubicin-polymer
conjugates using mesenchymal stem cells
for glioma therapy. Biomaterials, 39: 269-
Zhang Y, Kim KH, Zhang W, Guo Y, Kim
SH, Lü J. 2012. Galbanic acid decreases
androgen receptor abundance and signaling
and induces G1 arrest in prostate cancer
cells. Int J Cancer, 130: 200-212.
Zhao Y, Tang S, Guo J, Alahdal M, Cao S,
Yang Z, Zhang F, Shen Y, Sun M, Mo R.
2017. Targeted delivery of doxorubicin by
nano-loaded mesenchymal stem cells for
lung melanoma metastases therapy. Sci
Rep, 7: 1-12.